-
Dyne hopes to bring new treatment for DM1 to US market in 2028
Dyne Therapeutics expects to report top-line data in early 2027 from its Phase 1/2 ACHIEVE
-
Avidity’s trial for individuals with Duchenne amenable to skipping exon 45 is aiming to start in the first half of 2027
Read Avidity’s Community Letter: Avidity Community Letter_DMD45 Program Update_June 2026Download The post Avidity’s trial for








